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The Influence of an Inhaled Steroid on 
Quality of Life in Patients With Asthma or 
COPD*
Constant P. van Schayck, PhD; Edward Dompeling3 PhD, MD; 
Maureen P.M .H . Rutten, PhD; Hans Folgering, M D;
Guido van den Boom, MSc; and Chris van Weel, MD
Relatively little is known about the influence of inhaled 
corticosteroids on general well-being (quality of life) in 
patients with asthma or COPD. In a 4-year prospective 
controlled study, we examined the influence of beclo- 
methasone dipropionate (BDP), 400 ¡ig, two times daily, 
on quality of life in 56 patients with asthma or COPD 
in comparison with the effects of BDP on symptoms and 
lung function. During the first 2 years, patients received 
only bronchodilator therapy with salbutamol or ipra­
tropium bromide. During the third and fourth years, 
additional treatment with BDP was given» Fifty-six pa­
tients (28 with asthma, 28 with COPD) with an annual 
decline in the forced expiratory volume in 1 s (FEVi) of 
at least 80 mL/yr in combination with at least two ex­
acerbations per year during bronchodilator therapy 
alone participated. Quality of life was assessed at the 
start and after 2 and 4 years by means of the Inventory 
of Subjective Health (ISH) and the Nottingham Health 
Profile (NHP). Although BDP significantly improved the 
course of lung function (FEVi) (p<0.0001), it did not 
improve the ISH score or the six dimensions of the NHP 
neither in asthma nor in COPD. Beclomethasone dipro­
pionate temporarily decreased respiratory symptoms 
during months 4 to 6 of BDP treatment in patients with 
asthma (p<0.01) and during months 7 to 12 in patients 
with COPD (p<0.05). A weak correlation was found 
both cross-sectionally and longitudinally between 
(change in) symptoms and quality of life on the one
hand, and the (change in) FEVi on the other. It was 
concluded that BDP did not improve the general well­
being of patients with asthma or COPD as measured by 
these generic health instruments. However, BDP signif­
icantly improved the course of lung function and 
temporarily decreased the severity of symptoms. It 
seems probable that changes in quality of life would 
have been better detected by use of a disease-specific 
health instrument. Such an instrument was not available 
at the start of the study. Another possible explanation for 
these observations is that patients soon get used to dif­
ferent levels of lung function and learn to live with their 
disease. It is advised that disease-specific health instru­
ments are used in future intervention studies and that 
quality of life is measured frequently during the early 
phase of the intervention, eg, once every month.
(Chest 1995; 107:1199-1205)
BDP=beclomethasone dipropionate; FEVi “ forced expira­
tory volume in 1 s; ISII=Inventory of Subjective Health; 
MRC=Medical Research Council; NHP=Nottingham 
Health Profile
Key words: asthma; beclomethasone dipropionate; COPD; 
inhaled corticosteroid; quality of life
reatment with inhaled corticosteroids has become 
increasingly important in asthma and (to a 
smaller degree) in COPD .1"4 Airway inflammation is 
an important pathophysiologic mechanism in asthma 
and perhaps also in COPD .5,6 Several short-term 
studies during some months7"10 and a few long-term 
studies during 1 or 2 years11"13 in asthma have shown 
that inhaled steroids are able to improve lung func­
tion, nonspecific bronchial responsiveness, symp-
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toms, exacerbations, and can reduce the need for 
bronchodilator therapy. There is less unanimity 
about the effects of corticosteroids in patients with 
COPD .14 A meta-analysis of short-term studies with 
systemic corticosteroids,15 a recent short-term trial,3 
and a retrospective long-term study4 suggested that 
corticosteroids are potentially beneficial in COPD. 
To our knowledge, no controlled studies have been 
published on the effects of inhaled steroids on qual­
ity of life in patients with asthma or COPD. Recently, 
in an uncontrolled study, Juniper et al16 showed that 
quality of life was improved in patients who re­
sponded to an inhaled steroid. It is generally agreed 
that improving the health of patients is an important 
goal of therapeutic intervention.17
Patients with asthma and COPD may suffer from
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breathlessness, exercise limitation, anxiety and de­
pression, and problems related to social activi­
ties.1,17'20 The quality of life in patients with asthma 
or COPD was worse than in subjects of the general 
population.19,20 However, cross-sectional relation­
ships between objective measurements of the sever­
ity of the disease (as forced expiratory volume in Is 
[FEVi]) and quality of life have been shown to be 
poor, even when disease-specific questionnaires are 
used.21 As quality of life is an important outcome 
measurement for the patients themselves, it is im ­
portant to know whether treatment with inhaled 
corticosteroids not only improves the clinical out­
come measures of asthma or COPD but also the 
quality of life of patients with these diseases.
We studied the influence of an inhaled corticoste­
roid (beclomethasone clipropionate, BDP) on the 
quality of life in 56 patients (28 with asthma, 28 with 
COPD) in a prospective controlled study. The influ­
ence of BDP on quality of life was compared with the 
effects on symptoms and lung function. We did not 
use disease-specific questionnaires as these instru­
ments were not available at the start of the study.
M et h o d s
Patients
Fifty-six patients (28 with asthma, 28 with COPD) with an 
annual decline in FEVj of at least 80 mL/yr in combination with 
at least two exacerbations per year participated in this 4-year 
study.22 The criteria for diagnosis of asthma or COPD were based 
on the standards of the American Thoracic Society.18,22 The study 
was approved by the Medical Ethics Committee of the Univer­
sity of Nijmegen. All patients gave informed consent.
Study Design ancl Treatment
At the start of the 4-year intervention study, the patients were 
randomly allocated to one of the t wo parallel treatment regimens: 
continuous (four times daily) or on demand (only dry powder 
inhalations during periods of complaints) bronchodilator thera­
py.23 In the third and fourth year, the 56 patients were addition­
ally treated with BDP, 400 /¿g, two times daily. Outcome measures 
during treatment with bronchodilators alone (first 2 years) were 
compared with those during additional BDP therapy (third and 
fourth years of study) in a self-controlled design, which is known 
to produce equally valid results as the parallel study design.24
Measurements
Baseline Characteristics: At the start of the study, smoking 
behavior, allergy, lung function (FEVi and FEVi/inspiratory 
vital capacity (IVC), reversibility, diurnal peak-flow rate index, 
and bronchial responsiveness to histamine were assessed.22
Reversibility was assessed by the increase in FEVi, 1 h after the 
administration of salbutamol, 400 /ig, and ipratropium bromide, 
80 /u.g, and it was expressed as a percentage of the predicted value 
of FEVi, The diurnal peak-flow rate index was determined by the 
absolute difference between the weekly measured evening and 
morning peak flow (same day and time of day) divided by the 
highest value of that day for a period of 4 weeks. Bronchial re­
sponsiveness to histamine was measured according to the method
of Cockcroft et al23 and expressed as the provoking concentration 
of histamine that produced a 20% fall in FEVi (PC20 value).
Outcome Measures: Quality of life was measured by complet­
ing two questionnaires, viz, the Dutch version of the Nottingham 
Health Profile (NHP)20,26'30 and the Inventory of Subjective 
Health (ISH).20 The NHP is a generic, self-administered ques­
tionnaire designed to measure perceived physical, emotional, and 
social health problems. The emphasis is on the respondent’s sub­
jective perception of his or her health status.26 The NHP contains
38 statements relating to 6 dimensions: physical mobility (8 
statements), pain (8 statements), social isolation (5 statements), 
emotional reactions (9 statements), energy (3 statements), and 
sleep (5 statements). The statements were taken from interviews 
with patients suffering from various acute or chronic diseases, and 
from other health questionnaires like the Sickness Impact Profile. 
All statements are formulated in such a way that they can be an­
swered by yes or no. McKenna et al27 derived the weights from 
a sample of both patients and healthy subjects using Thurstone’s 
method of perceived health problems. Separate NHP dimension 
scores are presented as a profile, not integrated into an overall 
score. Although the NHP was originally developed as a survey 
instrument to measure perceived health status in a population, it 
has been used extensively in evaluation studies and is claimed to 
be sensitive to change in disease severity.20“30 The NHP has 
proved to be reliable and can be administered easily, with small 
demands on patient time and effort,2t} The higher the score, the 
more physical complaints are reported. The ISH is a generic, 
commonly used Dutch scale that contains 21 questions related to 
subjective physical complaints like tiredness, chest and heart 
problems, gastric problems, indigestion, headache, etc. Most 
complaints can be grouped according to the organ system to 
which they are referred. The remaining ones relate to the over­
all physical condition. The ISH statements were taken partly from 
the Cornell Medical Index and completed with statements from 
expert-interviews about the influence of physical stress on health. 
The internal consistency and reliability of the ISH are strong and 
answers do not appear to be influenced by social desirability.20 
The overall ISH score is made up by the number of affirmative 
answers. The more physical complaints are reported, the higher 
the score. Quality of life was assessed at the start and after 2 and 
after 4 years of study.
Respiratory symptoms were assessed by means of two ques­
tionnaires. First, the questionnaire of the Medical Research 
Council (MRC) (Dutch version) was used at the start and after 2 
and 4 years of study.23 A total score (MRC-symptom score) of 0 
to 8 was determined from the answers to eight different ques­
tions.23 Second, patients made weekly recordings of severity of 
cough, phlegm, and dyspnoea on a scale of 0 to 4. The separate 
scores together made up the total symptom score.
The FEVi was assessed by means of the Microspiro HI-298 
(Chest Corporation, Japan).31
Analysis
No period or carryover effects were present in this self- 
controlled trial.32 Regression-to-the-mean appeared to explain 
only a small, negligible part of the improvements in FEVi dur­
ing BDP therapy.22
The annual decline in FEVi during bronchodilator therapy 
alone was estimated by linear regression of FEVi in the course of 
time, Because of a nonlinear change in FEVi during BDP treat­
ment, the FEVj values at the end of BDP treatment were com­
pared with those at the start. The changes in the quality of life 
scores before and during BDP treatment were statistically com­
pared by the Wilcoxon matched-pairs signed-ranks test (because 
the distribution was not normal), changes in FEVi by the 
unpaired Student’s t test. Correlations between the change in 
quality of life and MRC-score on the one hand and the change in
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Table 1— Clinical Characteristics of the Patients With 
Asthma and COPD at the Start of the 4-Year
Intervention Study*
Variable Asthma COPD
No. 28 28
Age, yr 49 (12) 52 (10)
Sex, M/F ■ 12/16 16/12
Pack-years 13(14)f 23 (17)
Smokers, ± 14/14 19/9
Cigaretles/day 4.2 (6.7)t 10.0 (9.2)
Allergy, ±* 14/141 4/24
FEVi, %pred 67 (17) 70 (16)
FEVi/IVC, %55 57 (15) 63 (13)
Reversibility FEVi, % pred 14 (9)} 7(4)
Diurnal PEFRfl index, % 12 (8) 9(5)
PC20, (mg/mL) 0.8| 6.2
MRC symptom score 4.9 (1.8) 5.5 (1.7)
ISH 6.3 (4.6)t 9.5 (4.6)
NHP score
Energy 30.2 (38.7) 35.1 (37.2)
Pain 12.4 (26.0) 19.1 (28.8)
Emotions 12.5 (19.3) 15.8 (26.5)
Sleep 19.2 (29.1) 27.1 (23.9)
Social isolation 13.7 (27.9) 12.3 (25.6)
Physical mobility 12.0 (20.9) 12.8 (13.8)
*Differences between asthma and COPD were statistically compared 
by the unpaired Student's t test for normally distributed variables, 
the x2 test for dichotomous variables, and the Mann-Whitney U test 
for continuous not-normaliy distributed variables. SD between pa­
rentheses. 
tp<0.05. 
tp<0.001.
§Allergy was defined as at least one positive test out of seven RAST, 
§§IVC=inspiratory vital capacity,
||PEFR=peak expiratory flow rate,
FEVj on the other were calculated both before and during BDP 
therapy (longitudinal analysis). Besides, correlations among qual­
ity of life, symptoms, and lung function were assessed cross sec- 
tionally (between-patient analysis).
Clinical characteristics of asthmatics and patients with COPD 
were statistically compared by the unpaired Student’s t test for 
normally distributed variables, the x2 test for dichotomous 
parameters, and the Mann-Whitney U test for continuous, not 
normally distributed variables.
R esults 
Baseline Characteristics
At the start of the 4-year study, asthmatics were 
characterized by less past and current smoking, a 
higher percentage of allergy, a higher reversibility, 
and a more severe bronchial hyperresponsiveness 
than patients with COPD (Table 1). Quality of life as 
assessed by the ISH score was worse in patients with 
COPD than in patients with asthma (Table 1).
Of the 56 patients, 48 completed treatment with 
BDP. Reasons for dropping out were as follows: re­
fusal to use corticosteroids (one with asthma, one with 
COPD); bronchial carcinoma (one with COPD); 
chronic heart failure (one with COPD); persistent 
oral candidiasis and dysphonia (two with COPD);
and personal (nonmedical) reasons (one with asthma,
one with COPD).
Quality of Life of Study Population in 
Comparison W ith a Random Sample of the 
Population
Compared with data in the general population,26 
quality of life at the start of our study appeared to be 
impaired in the asthmatics and patients with COPD 
(Fig 1). W ith the exception of the emotional reaction 
score and the sleep score of the NHP, the quality of 
life scores in our patients with asthma or COPD were, 
on average, two to three times higher than in the 
general population (Fig 1).
The influence of BDP on Quality of Life, 
Symptoms, and Lung Function
In Table 2 , the changes in quality of life, MRC- 
symptom score, and FEVi during the 2-year study 
period before the use of BDP and during BDP treat­
ment are shown. No significant changes in the qual­
ity of life and symptom scores were found in patients 
with asthma either before treatment with BDP or 
during BDP therapy (all p values >0.17) (Table 2). 
Also, when the changes in quality of life scores before 
BDP treatment were compared with those during 
BDP therapy, no significant improvements were ob­
served in patients with asthma (all p values >0.48). 
In patients with COPD, however, the MRC symptom 
score, the emotional reaction score, and the social 
isolation score of the NHP improved significantly 
before BDP treatment despite a substantial worsen­
ing of the FEVi (Table 2). During BDP therapy, no 
significant changes in quality of life were found in 
patients with COPD.
In patients with asthma, the severity of weekly 
recorded symptoms showed a decrease of 17% dur­
ing the first 3 months of treatment with BDP 
compared with the period before BDP was given 
(p<0.01) (Fig 2). During the rest of the treatment 
period, no significant improvements were found for 
the weekly symptom score. In patients with COPD, 
the severity of weekly recorded symptoms was only 
significantly reduced during months 7 to 12 of BDP 
treatment (13%, p<0.05) (Fig 2).
Both in patients with asthma and COPD, the 
course of lung function improved by BDP treatment. 
The FEVi deterioration of — 160(SEM 20) mL/yr 
before BDP differed from the change of +10(23) 
mL/yr during BDP (paired Student's t test, 
p<0.0001). This effect was more evident in asthmat­
ics (—173 vs +38 m L/ yr) than in patients with COPD 
(—146 vs —23 mL/yr).
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F ig u re  1. Quality-of-life scores in patients 
with asthma and COPD of this study com­
pared with the general population.
Longitudinal Correlation Between the Change in 
Quality of Life or Symptoms and the Change in 
Lung Function
In general, there was only a weak correlation 
within patients between the change in quality of life 
or MRC symptom scores on the one hand and the 
change in FEVi on the other, both in asthma and 
COPD (Table 3). The only statistically significant 
findings were those of the energy score of the NHP. 
In patients with asthma, the change in the energy
score was related to the change in FEVi during 
bronchodilator therapy alone (r=0.44, p<0.05). In 
patients with COPD, the change in energy score was 
related to the change in FEVi, during additional 
BDP treatment (r3* —0.46, p<0.05).
Cross-Sectional Correlation Among Quality of 
Life, Symptoms? and Lung Function
When the quality of life and MRC symptom scores 
were related to the FEVi at the start, after 2 and af-
Table 2— Changes in Quality-of Life Scores, MRC Symptom Scores, and Lung Function Before
and During the Use of BDP*
Before BDP During BDP
Change in P Change in P
Asthma
ISH -0,27 (0.49) 0.59 -0.68 (0.66) 0.31
NHP
Energy +5.5 (4.0) 0.18 +0.4 (4.8) 0.94
Pain -1.5 (3.4) 0.66 +0.5 (2.5) 0.85
Emotional reaction +1.2 (4,2) 0.78 +0.2 (3.1) 0.94
Sleep -0.10(3.8) 0.98 -3.0 (3.7) 0.43
Social isolation +2.7 (4.1) 0.51 +0.5 (3.1) 0.87
Physical mobility +43 (3.0) 0.17 +0.5 (2.5) 0.84
MRC symptom score +0.12(0.37) 0.75 +0.24 (0.31) 0.45
FEVj, mL/yr “ 173 (22) 0.0001 +38 (30) 0.22
COPD
ISH +1.2 (0.6) 0.065 -1.3 (0,9) 0.18
NHP
Energy +6.8 (4.9) 0.18 -3.4 (6.1) 0.59
Pain +2.0 (5.1) 0.69 -6.7 (4.7) 0.18
Emotional reaction +7.3 (2.5) 0.01 -2.4 (2.4) 0.34
Sleep -2.6 (4.3) 0.55 -0.8 (7.3) 0.91
Social isolation +4.4 (2.0) 0.04 -0.3 (3.6) 0.94
Physical mobility + 1.1 (2.4) 0.64 -2.2 (2,4) 0.38
MRC symptom score + 1.14(0.40) 0.009 -0.25 (0.33) 0.46
FEVi, mL/yr -146 (36) 0.0006 -23 (35) 0.52
*SEM between parentheses. A negative change in quality of life and MRC score implies a deterioration; a positive sign, an improvement,
1202 Clinical Investigations
Figuhe 2. Weekly recorded symptom score at 3-month intervals 
in the 4-year study period in patients with asthma and COPD.
ter 4 years of study, it appeared that no significant 
correlations were found either in patients with asthma 
(the absolute value of r ranged from 0.004 to 0.39, 
p>0.05) or in patients with COPD (absolute value of 
r ranged from 0.005 to 0.38, p>0.06).
D iscussion
The most important observation of this study was
that BDP significantly improved the course of lung 
function, while there was no evidence that the qual­
ity of life measured by generic instruments was 
changed. BDP diminished the severity of symptoms 
only significantly for some months during the first 
year of BDP treatment. During the rest of the treat­
ment period, no influence on symptoms was found 
either in the weekly recorded symptom score or in the 
2-yearly measured MRC symptom score. The sub­
stantial decline in lung function with bronchodilator 
therapy alone was not accompanied by a significant 
worsening of quality of life in this period. In fact, 
some of the scores even improved significantly in this 
part of the trial in patients with COPD. This may be 
explained by an '"in care” effect because of partici­
pation in the trial. All these findings together may 
suggest that patients soon get used to different levels 
of airway obstruction and learn to live with their 
disease. Their perception of the severity of their 
disease may be limited .17 Perhaps we could have 
found a positive effect of BDP on quality of life if 
we had measured this variable frequently in the first 
year of BDP, like for symptoms. It seems advis­
able that quality of life is measured frequently 
during the early phase of the intervention, eg, 
once every month.
Apart from the frequency, there is some reason to 
doubt that generic health instruments as NHP and 
ISH are able to detect changes in quality of life of 
patients with asthma. In the present study, these in­
struments have been shown to be able to detect an 
impaired subjective well-being when compared with 
the general population. Comparable observations
Table 3—Correlation Between the Changes in Quality of Life Scores, the MRC Symptom Scores, and the Changes in
FEVi Before and During the Use of BDP (Within-Subject Analysis)
Before BDP During BDP
r P r P
Asthm a
ISH +0,11 0.59 ”“0.33 0.10
NHP
Energy +0.44 0.023 +0.11 0.60
Pain -0.07 0.72 -0.02 0.91
Emotional reaction +0.35 0.076 -0.34 0.096
Sleep “ 0.34 0.09 +0.26 0.20
Social isolation +0.30 0.14 -0.17 0.42
Physical mobility +0.35 0.077 +0.20 0.34
MRC symptom score -0.06 0.75 +0.23 0.25
COPD
ISH -0.19 0.39 -0.14 0.57
NHP
Energy -0.18 0.41 -0.46 0.039
Pain -0.05 0.81 -0.23 0.33
Emotional reaction +0.11 0.63 -0.18 0.44
Sleep -0.29 0.22 -0.15 0.54
Social isolation -0.22 0.32 +0.18 0.44
Physical mobility +0.30 0.18 -0.03 0.89
MRC symptom score -0.04 0.85 +0.32 0.14
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were done in other studies with patients with hyper­
tension,35 myocardial infarction,34 coxarthrosis35 
stroke,36 and asthma.37 However, this does not mean 
that these instruments are able to detect differences 
in quality of life of asthmatic patients during, for 
example, a therapeutic intervention. It was recently 
shown that the Sickness Impact Profile (a generic 
questionnaire with partly the same questions as the 
NHP) could not detect changes in quality of life, 
while a more specific questionnaire could detect 
differences.38 Similar observations were done in other 
recent studies.16,39,40 A disease-specific health instru­
ment has the advantage of covering specific aspects 
of the clinical disorder under study that are not rel­
evant for a generic well-being scale.41 Examples of 
disease-specific quality of life scales of asthma or 
COPD have only recently become available16,21,38"40 
and experience with these scales is therefore limited. 
Unfortunately, disease-specific questionnaires were 
not available at the start of the present study.
A comparison of the ISH and NHP scores in our 
patients with asthma and COPD with data from the 
general population26 revealed that patients experi­
ence their disease as important for their general 
well-being. Quality of life seemed impaired in pa­
tients with asthma and COPD when compared with 
the general population, although this simple com­
parison must be interpreted with caution. Most of the 
quality of life scores were two to three times higher 
in the patients of this study than in samples of the 
general population. Patients with asthma or COPD 
may suffer from breathlessness, exercise limitation, 
anxiety and depression, and problems related to so­
cial activities.1,17'20 Quality of life may be more dis­
turbed in patients with COPD than in asthmatics.18 
In our study, quality of life as assessed by the ISH was 
worse in patients with COPD than in patients with 
asthma. This difference was not found for the six di­
mensions of the NHP. In patients with COPD, 
obstruction as well as respiratory complaints are of a 
sustained, chronic character.18 In patients with 
asthma, the degree of airflow limitation varies con­
siderably in the course of time and symptom-free 
intervals may alternate with periods of cough, wheez­
ing, and dyspnea.18 The ISH is particularly directed 
at chronic physical complaints20 and it is therefore 
logical that patients with COPD had a higher ISH 
score than asthmatics.
We investigated the correlation between the qual­
ity of life scores, MRC symptom score and the FEVi 
both cross-sectionally and longitudinally. In asthma 
as well as in COPD, the correlations between lung 
function and quality of life scores were weak with 
only two (opposite) significant correlations for the 
energy score of the NHP. In general, correlations 
within subjects (longitudinal analysis) were slightly
higher than between subjects (cross-sectional analy­
sis). Many other studies found a low correlation be­
tween all kinds of quality of life scales and the lung 
function level.19'21,42'45 It has been suggested that the 
attitude to health or disease interferes with the rela­
tion between lung function and the results of psy­
chometric tests.46 This general attitude toward health 
or disease may be the reason that a lower lung func­
tion level is not necessarily accompanied by a lower 
experienced quality of life.
We conclude that treatment with BDP (in com­
parison with bronchodilator treatment alone) did not 
improve the general well-being of patients with 
asthma or COPD as measured by generic instruments 
despite a positive influence of BDP on the course of 
lung function and a temporary reduction in severity 
of symptoms in these diseases. Neither the substantial 
decline in lung function during bronchodilator ther­
apy alone nor the improvement in the course of lung 
function during BDP therapy was accompanied by 
corresponding changes in the generic quality of life 
scores. An explanation for these findings may be the 
disability of the generic instruments to detect dif­
ferences and that patients soon get used to different 
levels of lung function and learn to live with their 
disease. We recommend that quality of life in future 
intervention studies is measured by disease-specific 
health instruments. During the early phase of the 
intervention, quality of life must be measured fre­
quently, eg, once every month.
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